Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease

NCT03846479 is registered in ClinicalTrials.gov with John Levine as lead sponsor.

NCT NCT03846479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03846479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Lead sponsor
John Levine
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2019
Completion date
May 11, 2022
Enrollment
70 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host-disease, gvhd, low risk acute graft-versus-host disease